Role of LIBC in Inflammatory Breast Cancer Phenotype
LIBC 在炎症性乳腺癌表型中的作用
基本信息
- 批准号:7276086
- 负责人:
- 金额:$ 13.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-30 至 2008-08-31
- 项目状态:已结题
- 来源:
- 关键词:6q21AddressAgarAmino Acid SequenceAngiogenesis InhibitorsAngiogenic FactorAngiogenic SwitchAntibodiesApoptosisBindingBiological AssayBiological ProcessBreast CarcinomaCarcinomaCellsClinicalDermalDetectionDevelopmentDistantEmbolismEmployee StrikesEnzyme-Linked Immunosorbent AssayEpithelialErythemaFamilyFamily memberFibroblast Growth Factor 2FoundationsGenesGrowthHumanImmunohistochemistryImmunoprecipitationIn VitroInflammatoryInsulin-Like Growth Factor IIInsulin-Like Growth Factor ReceptorInsulin-Like Growth-Factor-Binding ProteinsInvadedLaboratoriesLightLymphaticMalignant NeoplasmsMammary Gland ParenchymaMammary NeoplasmsMesenchymalModelingMolecularMusMutagenesisMutationNipplesNormal tissue morphologyNude MiceNumbersPECAM1 genePathologicPatientsPeau d&aposorangePhenotypePlayPrognostic MarkerPropertyProtein FamilyProtein Sequence AnalysisProteinsRecombinant IGF-IResearch DesignResearch PersonnelResectedRoleS cerevisiae SWI3 proteinSerumSiteSkinSomatomedinsStagingStructure-Activity RelationshipSymptomsTestingTherapeutic InterventionTissue MicroarrayTransfectionTumor Suppressor GenesVascular Endothelial Growth FactorsVascularizationWISP3 geneWorkangiogenesisbasecancer cellcarcinogenesiscell growthconnective tissue growth factordensitydesignhuman WISP3 proteinin vivoinsulin-like growth factor binding protein-related protein 1malignant breast neoplasmmembernovelnovel therapeuticsprogramsprotein expressionresearch studytranslational studytumortumor growthtumor progression
项目摘要
DESCRIPTION (provided by applicant): Inflammatory breast cancer (IBC) is the most lethal form of locally advanced breast cancer with unique clinical and pathologic features. Clinically, patients present with skin erythema and nodularity; pathologically, IBC is highly angiogenic and angioinvasive with multiple tumor emboli that plug the dermal lymphatics and are responsible for the striking clinical picture. Recently, a novel gene, WISP3 (LIBC) whose expression is lost in 80% of IBC and in 20% of non-IBC tumors has been identified in our laboratory. WISP3 gene belongs to the CCN family of proteins together with connective tissue growth factor, Cyr61 and NOV. Based on amino acid sequence analysis, WISP3 encodes for a putative IGF-binding protein related protein. We demonstrated that WISP3 has growth, invasion and angiogenesis inhibitory functions in breast cancer, both in vivo and in vitro. We hypothesize that loss of WISP3 expression results in unregulated breast cancer growth and angiogenesis by two possible mechanisms: 1. increasing the availability of IGF to the IGF receptor on epithelial and mesenchymal cells, and 2. directly through IGF-independent effects. The broad, long-term objectives of this proposal are to elucidate the role of WISP3 in breast cancer development and progression. In order to test this hypothesis and address the broad objective, we propose the following aims: 1) To elucidate the structure-function relationship of the WISP3 protein, and its relationship to the IGF family, 2) To investigate the role of WISP3 in breast cancer growth and in the in vivo angiogenic switch, and 3) To investigate the usefulness of detecting WISP3 protein as a potential prognostic marker in patients with breast cancer. The research design to study the structure/function relationship of the WISP3 protein involves immunoprecipitation and binding assays utilizing WISP3 protein and recombinant IGF-I and IGF-II. The relevance of the IGFBP domain in WISP3 function will be studied using mutagenesis assays of the IGFBP domain of the WISP3 protein, followed by transfection experiments and functional biological assays, including growth in soft agar, invasion, and angiogenesis assays. The in vivo role of WISP3 in the angiogenic switch involves the development of mammary tumors in athymic nude mice derived from transfected cells with different WISP3 protein expression and detection of angiogenic factors in the mice serum using ELISA assays. Immunohistochemistry of the resected mice tumors will be performed using antibodies for VEGF, bFGF and CD31. The translational study of patients' breast cancers and normal breast tissues will complete these experiments and involves immunohistochemistry for WISP3, CD31 and apoptosis, as well as development of a high-density tissue microarray. The experiments proposed may provide the foundation for the design of new therapeutic interventions that target WISP3. Also, understanding the role of WISP3 will shed light on the mechanisms of cancer development in general and serve as a model for other related CCN genes involved in carcinogenesis.
描述(申请人提供):炎症性乳腺癌(IBC)是局部晚期乳腺癌中最致命的一种,具有独特的临床和病理特征。临床表现为皮肤红斑和结节性;病理上,IBC是高度血管生成和血管侵入性的,有多个肿瘤栓子堵塞真皮淋巴管,这是引起显著临床表现的原因。最近,我们实验室发现了一个新的基因WISP3 (LIBC),它在80%的IBC和20%的非IBC肿瘤中表达缺失。WISP3基因与结缔组织生长因子、Cyr61和11一起属于CCN蛋白家族。根据氨基酸序列分析,WISP3编码一种推定的igf结合蛋白相关蛋白。我们在体内和体外均证明了WISP3在乳腺癌中具有生长、侵袭和血管生成抑制功能。我们假设WISP3表达的缺失通过两种可能的机制导致不受调节的乳腺癌生长和血管生成:1。1 .增加上皮细胞和间充质细胞上IGF受体的可用性;直接通过与igf无关的作用本研究的长期目标是阐明WISP3在乳腺癌发生和发展中的作用。为了验证这一假设并解决广泛的目标,我们提出以下目标:1)阐明WISP3蛋白的结构-功能关系及其与IGF家族的关系;2)研究WISP3在乳腺癌生长和体内血管生成开关中的作用;3)研究检测WISP3蛋白作为乳腺癌患者潜在预后标志物的有效性。为了研究WISP3蛋白的结构/功能关系,本研究设计了利用WISP3蛋白和重组IGF-I和IGF-II进行免疫沉淀和结合试验。IGFBP结构域与WISP3功能的相关性将通过WISP3蛋白IGFBP结构域的诱变试验进行研究,随后进行转染实验和功能生物学试验,包括软琼脂生长、侵袭和血管生成试验。在体内,WISP3在血管生成开关中的作用涉及由转染不同WISP3蛋白表达的细胞衍生的胸腺裸鼠乳腺肿瘤的发展,以及用ELISA法检测小鼠血清中的血管生成因子。使用VEGF、bFGF和CD31抗体对切除的小鼠肿瘤进行免疫组化。乳腺癌患者和正常乳腺组织的转化研究将完成这些实验,涉及WISP3、CD31和细胞凋亡的免疫组化,以及高密度组织芯片的开发。所提出的实验可能为设计针对WISP3的新治疗干预提供基础。此外,了解WISP3的作用将揭示癌症发展的一般机制,并作为其他相关CCN基因参与癌变的模型。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Celina G Kleer其他文献
Celina G Kleer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Celina G Kleer', 18)}}的其他基金
The Function of EZH2 in Estrogen Receptor Negative Breast Cancer in Women of Af
EZH2在AF女性雌激素受体阴性乳腺癌中的作用
- 批准号:
8532854 - 财政年份:2010
- 资助金额:
$ 13.57万 - 项目类别:
The Function of EZH2 in Estrogen Receptor Negative Breast Cancer in Women of Af
EZH2在AF女性雌激素受体阴性乳腺癌中的作用
- 批准号:
8149926 - 财政年份:2010
- 资助金额:
$ 13.57万 - 项目类别:
The Function of EZH2 in Estrogen Receptor Negative Breast Cancer in Women of Af
EZH2在AF女性雌激素受体阴性乳腺癌中的作用
- 批准号:
8307505 - 财政年份:2010
- 资助金额:
$ 13.57万 - 项目类别:
The Function of EZH2 in Estrogen Receptor Negative Breast Cancer in Women of Af
EZH2在AF女性雌激素受体阴性乳腺癌中的作用
- 批准号:
8014602 - 财政年份:2010
- 资助金额:
$ 13.57万 - 项目类别:
The Function of EZH2 in Estrogen Receptor Negative Breast Cancer in Women of Af
EZH2在AF女性雌激素受体阴性乳腺癌中的作用
- 批准号:
8707400 - 财政年份:2010
- 资助金额:
$ 13.57万 - 项目类别:
Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
CCN6 (WISP3) 在乳腺癌进展和转移中的作用
- 批准号:
8305594 - 财政年份:2008
- 资助金额:
$ 13.57万 - 项目类别:
Role of CCN6 (WISP3) in the Progression and Metastasis of Breast Cancer.
CCN6 (WISP3) 在乳腺癌进展和转移中的作用。
- 批准号:
8777055 - 财政年份:2008
- 资助金额:
$ 13.57万 - 项目类别:
Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
CCN6 (WISP3) 在乳腺癌进展和转移中的作用
- 批准号:
7529379 - 财政年份:2008
- 资助金额:
$ 13.57万 - 项目类别:
Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
CCN6 (WISP3) 在乳腺癌进展和转移中的作用
- 批准号:
10447058 - 财政年份:2008
- 资助金额:
$ 13.57万 - 项目类别:
Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
CCN6 (WISP3) 在乳腺癌进展和转移中的作用
- 批准号:
10676901 - 财政年份:2008
- 资助金额:
$ 13.57万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 13.57万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 13.57万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 13.57万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 13.57万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 13.57万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 13.57万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 13.57万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 13.57万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 13.57万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 13.57万 - 项目类别:
Research Grant